Kezar Life Sciences (NASDAQ:KZR) Given “Market Perform” Rating at William Blair

William Blair reiterated their market perform rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a research note released on Wednesday,RTT News reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, October 14th.

Kezar Life Sciences Trading Up 0.7 %

KZR stock traded up $0.05 during mid-day trading on Wednesday, reaching $7.54. 35,765 shares of the stock traded hands, compared to its average volume of 74,179. Kezar Life Sciences has a one year low of $5.20 and a one year high of $11.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 9.58. The stock has a market capitalization of $55.01 million, a PE ratio of -0.57 and a beta of 0.22. The business has a 50-day moving average price of $7.13 and a two-hundred day moving average price of $6.84.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($2.80) EPS for the quarter, beating the consensus estimate of ($3.20) by $0.40. Equities research analysts expect that Kezar Life Sciences will post -11.95 EPS for the current year.

Institutional Investors Weigh In On Kezar Life Sciences

Hedge funds have recently added to or reduced their stakes in the company. Mackenzie Financial Corp purchased a new stake in Kezar Life Sciences in the second quarter valued at approximately $35,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Kezar Life Sciences in the 2nd quarter worth approximately $63,000. BNP Paribas Financial Markets grew its stake in Kezar Life Sciences by 35.4% during the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after buying an additional 71,543 shares during the last quarter. Acuitas Investments LLC boosted its position in Kezar Life Sciences by 42.8% during the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after acquiring an additional 295,956 shares during the period. Finally, Stonepine Capital Management LLC bought a new position in Kezar Life Sciences during the second quarter valued at about $630,000. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.